Authors
Latest:
Dr. Chandarlapaty on Responses to Amcenestrant/Palbociclib in ER+/HER2- Metastatic Breast CancerSarat Chandarlapaty, MD, PhD, highlights responses to amcenestrant and palbociclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer, as seen in the phase 1/2 AMEERA 1 trial.
Latest:
Dr. Neelapu on Managing Toxicities Associated with CAR T-Cell Products in LymphomaSattva Neelapu, MD, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.
Latest:
Dr. Neelapu on Long-Term Follow-Up of ZUMA-5 With Axicabtagene Ciloleucel in R/R Non-Hodgkin LymphomaSattva S. Neelapu, MD, discusses the long-term follow-up analysis of the phase 2 ZUMA-5 trial with axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Latest:
Oncologists Must Help Patients Overcome Fear of Genetic Testing to Uncover Cancer RisksIn the current digital age, where all-too-personal information flows from Facebook and Twitter, it seems that the health information available through the process of genetic testing would be an idea welcomed by most of the public.
Latest:
Dr. Chhabra on Impactful Advances in Relapsed/Refractory Multiple MyelomaSaurabh Chhabra, MD, MS, assistant professor at the Medical College of Wisconsin, discusses the most impactful advances made in relapsed/refractory multiple myeloma.
Latest:
Higher Incidence, New Therapies Add to Cost of Treating Advanced Pancreatic CancerPancreatic cancer is one of the few cancers that is on the rise, and this means that the overall cost of treating this disease is also climbing.
Latest:
Evolving Strategies Using Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Non-Hodgkin LymphomaDiffuse large B-cell non-Hodgkin lymphoma is typically a chemotherapy-sensitive malignancy, justifying dose-intense therapy with hematopoietic stem cell transplantation for patients unlikely to achieve cure with standard-dose regimens.
Latest:
Dr. Eggener on PSA-Based Screening in Early-Stage Prostate CancerScott Eggener, MD, associate professor of Surgery, Urologic Oncology, at the University of Chicago Medicine, discusses his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer. Eggier shared these thoughts during the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.
Latest:
Dr. Gettinger on Lung Cancer ImmunotherapiesScott Gettinger, MD, associate professor of medicine (medical oncology), Yale School of Medicine, explains the development of immunotherapies in lung cancer.
Latest:
Dr. Glaser on Managing Radiation-Induced AEs in Early Breast CancerScott Glaser, MD, assistant clinical professor of radiation oncology, City of Hope, discusses strategies for managing radiation-induced adverse events in patients with early-stage breast cancer.
Latest:
The Use of Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumors (GIST)In this review article, the author discusses the use of tyrosine kinase inhibitors in the management of patients with gastrointestinal stromal tumors.
Latest:
Dr. Antonia on Investigational Immunotherapy Combinations in Stage III NSCLCScott J. Antonia, MD, PhD, instructor, Duke University School of Medicine, member, Duke Cancer Institute, discusses investigational immunotherapy combinations in stage III non–small cell lung cancer (NSCLC).
Latest:
Dr. Swanson on Treating Multifocal Lung CancerScott J. Swanson, MD, co-director of Minimally Invasive Surgery and chief surgical officer at Brigham and Women’s Hospital, professor of Surgery at Harvard Medical School, discusses treating multifocal lung cancer.
Latest:
Dr. Swanson on Surgical Choices for Multifocal Lung CancerScott J. Swanson, MD, co-director of Minimally Invasive Surgery and chief surgical officer at Brigham and Women’s Hospital, professor of Surgery at Harvard Medical School, discusses surgical choices for patients with multifocal lung cancer.
Latest:
Dr Kopetz on Adagrasib Plus Cetuximab in KRAS G12C+ mCRCScott Kopetz, MD, PhD, FACP, discusses the clinical efficacy and safety of adagrasib plus cetuximab in patients with KRAS G12C-mutated mCRC.
Latest:
Anticipating Key Studies and Pipeline Treatments in mCRC LandscapeThe experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Latest:
Dr. Scott Rowley on Allogeneic Stem Cell TransplantScott Rowley, MD, the Chief of John Theurer Cancer Center's Blood and Marrow Stem Cell Transplantation Division, discusses the challenges of allogeneic stem cell transplant.
Latest:
Dr. Samuelson on the Comorbidities that Affect Treatment Decisions in Prostate CancerScott Samuelson, MD, medical oncologist at Utah Cancer Specialists, discusses the comorbidities that may affect treatment decisions for patients with metastatic prostate cancer.
Latest:
Dr Tagawa on the Rationale for Investigating First-Line Nivolumab Plus Cisplatin in Urothelial CancerScott T. Tagawa, MD, MS, FACP, FASCO, discusses the rationale for evaluating nivolumab plus cisplatin-based chemotherapy in first-line urothelial cancer.
Latest:
Prostate Cancer Management: Future Directions in CareClosing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.
Latest:
Dr. Kim Discusses Minimally Invasive Surgery and Laparotomic Surgery in Cervical CancerSe Ik Kim, MD, research fellow, Department of Obstetrics and Gynecology, Seoul National University Hospital, discusses the use of minimally invasive surgery and laparotomic surgery in patients with cervical cancer.
